Журнал. Вестник офтальмологии № 6 — 2020 г.

Обзоры литературы

Literature reviews

Karateev AE, Nasonov EL, Ivachkin VT, Martynov AI, Uachno NN , Aru- tyunov G P i dr. Rational Use o f Nonsteroidal Anti-inflammatory Drugs. Clinical Guidelines. Nauchno-practicheskaya Revmatologiya. 2018;56(1):1- 29. (In Russ.). https://doi.org/10.14412/1995-4484-2018-l-29 46. Каратеев A .E ., Эрдес Ш .Ф. Применение нестероидных противовос­ палительных препаратов при АС долго и упорно! Терапевтический ар­ хив. 2014;86(Н): 123-127. Karateev АЕ, Erdes ShF. Use o f nonsteroidal an ti-inflamm atory drags in case o f ankylosing spondylitis long and persistenly! Terapevtisheskii arhiv. 2014;86(II): 123-127. (In Russ.). 47. Zochling J,Van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC , et al. Non-steroidal an ti-inflammatory drugs inhibit radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. EULAR. 2004; Abstracts, SP0077. 48. M unoz-Fe rnandez S, Hidalgo V, Fernandez-M e lon JL, Spabraw I, Sch- linker A, Bonilla G , Ruis-Sancho D, Fonseca F, et al. Sulfasalazine reduces the number o f flares o f acute anterior uveitis over a one-year period. J Rheu­ matol. 2003;30(6): 1277-1279. 49. Fiorelli VM, Bliat P, Foster CS. Nonsteroidal an ti-in f lamm a to ry therapy and recurrent acute anterior uveitis. Оси/ Immunol Inflamm. 2010; 18(2): 116-120. https://doi.org/10.3109/09273941003587558 50. Schjerning Olsen AM, Gislason GH , McGettigan P, Gerds TA, Fosbol TL, Olesen JB, Sinden-Pedersen C, Staerk L, et al. Association o f NSA ID use with risk o f bleeding and cfrdiovascular events in patients reseiving antithrom­ botic therapy after myocardial infarction. JAMA. 2015;313(8):805-814. https://doi.org/10.1001/jama.2015.0809 51. Moore A, Makinnson G , Li C. Patient-level pooled analysis o f adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis o f 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013; 15(1):6. https://doi.org/10.1186/ar4134 52. Foster CS, Vitale AT. Editors. Diagnosis and treatm en t o f uveitis. Filadel- phia. W В Saunders Company. 2002;900. 53. Levinson RD, Rosenbaum JT. Non steroidal Anti-inflammatory Drugs for prophylaxis o f Acute Anterior Uveitis. Оси/ Immunol and inflamm. 2010; 18(2):69-71. https://doi.org/10.3109/09273941003768224 54. Wood SG , F itzpatric K, Brodie R, Wright KU, Ellis ME. Pharmacokinet­ ics and metabolism a new N SAI D/analgesic aceclofenac in man. Pharm Res. 1990;7(9): 212. 55. Battle-Gualda E, Figueroa M, Ivorra J , Raber A. The efficacy and tolerabil- ity o f aceclofenac in the treatm en t o f patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol. 1996:23(7): 1200-1206. 56. Huskisson E, Irani M, Murray F. A large prospective open—label, multicen­ tre SAMM study, comparing the safety o f aceclofenac in patients with rheu­ matic disease. Eur J Rheumatol Inflamm. 2000; 17:1 -7.

57. Kroon FP, Van der Burg LR, Ramiro S, Laudewe RB, Buchbinder R, Fai­ son L, Van de r Heijde D. Nonsteroidal Antiinflammatory Drugs for axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016;43(3):607-617. h ttps://doi.org/10.3899/jrheum .150721 58. Савенков М .П ., Бродская C.A., Иванов C .H ., Судакова Н .И . Влияние нестсроидных противовоспалительных средств на антигипергензив- ный эфф ект ингибиторов АПФ . РМЖ. 2003;19:1056-1059. Savenkov М Р, Brodskaya SF, Ivanov SN , Sudakova N1. The effect o f non ­ steroidal anti-inflammatory drugs on the antihypertensive effect o f ACE in­ hibitors. RMZ. 2003;19:1056-1059. (In Russ.). 59. Angeli F, Trapasso M, Signorotti S, Verdeccia P, Reboldi G . Amlodipin and celecoxib for treatment o f hypertension and osteoarthritis pain. Expert Rev Clin Pharmacol. 2018; 11:1073. https://doi.org/10.1080/17512433.2018.1540299 60. Polonia J. Interaction o f antihypertensive drugs with anti-inflammatory drugs. Cardiology. 1997;88(3):47-51. https://doi.org/10.1159/000177507 61. Morgan T, Anderson A. The effect o f nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J. Clin Hypertens (Greenwith). 2003;5(l):53-57. 62. G am ie r P, Hwang E. Meloxicam versus usual care NSA IDs for the trea t­ ment o f osteoarthritis in the usual care setting. The results o f the IMPROVE trial. > 4 / 7/7 Rheum Dis. 2002;61(1):421. 63. Pelletier JP, Martel-Pelletier J. Effects o f nimesulide and naproxen on the degradation and metalloprotease synthesis o f human osteoarthritis cartilage. Drugs. 1993;43(l):34-39. https://doi.org/10.2165/00003495-199300461-00008 64. Rainsford K. Current status o f the therapeutic uses and actions o f the prefen- tial cyclo-oxygenase-2NSAID, nimesulide. Inflammopharmacology. 2006; 14: 120-137. h ttps://do i.org /10 .1007/s 10787-006-1505-9 65. Conforti A, Leone R, Moretti U, Mozza E, Velo G . Adverse drug reactions related to the use o f NSAIDs with a focus on nimesulide: results o f spon ta­ neous reporting from Northern Italian area. Drugs. 2001;24:1081-1090. https://doi.org/10.2l65/00002018-200124140-00006 66 . Каратеев A.E., Алексеева Л. И., Братыгина Е.А., Аширова Т .Б. Оценка частоты развития побочных эффектов при длительном использовании нимесулида в реальной клинической практике. Русский медицинский журнал. 2009; 12(21): 1466-1472. Karateev АЕ, Alekseeva LI, Bratygina ЕА, Aschirova ТВ. Assessment o f fre­ quency o f development o f side effects at long use o f a nimesulid in real c lin­ ical practice. Russkii MedicinskiiZhurnal. 2009; 17(21): 1466-1472. (In Russ.).

Поступила 17.05.2020 Received 17.05.2020 Принята к печати 02.06.2020 Accepted 02.06.2020

77

RUSSIAN ANNALS OF OPHTHALMOLOGY 6 , 2020